ReviewFrontiers in neuroscience2026
Astrocytic GABAergic signaling in perioperative neurocognitive disorders: mechanisms and intervention strategies.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perioperative neurocognitive disorders (PND) are a major burden for older surgical patients, yet little is known about the cellular events that set them in motion, and no therapy currently changes their course. Anesthesia and amnesia after etomidate, sevoflurane, or isoflurane depend mainly on gamma-aminobutyric acid type A receptors (GABA(A)Rs), and an increasing body of work shows that astrocytes also respond to these drugs. This review examines an astrocyte-centered GABAergic cascade that may link anesthetic exposure to PND and grades the strength of the evidence at each node. When anesthetics engage astrocytic GABA(A)Rs, reactive astrogliosis follows, astrocytic GABA synthesis rises through the monoamine oxidase B (MAOB)-dependent putrescine route, and Best-1-mediated release along with weaker GABA transporter-3 (GAT-3) clearance lets ambient GABA accumulate. Extrasynaptic α5-GABA(A)Rs then become overactive, tonic inhibition of hippocampal and subcortical neurons may grow, synaptic plasticity falters, and cognition declines. We weigh the evidence behind each stage, distinguish mechanisms established in PND models from those extrapolated from other conditions, identify the astrocyte-specific experiments that remain to be performed, and consider interventions that could break the cascade, spanning α5-GABA(A)R negative modulation, MAOB blockade, GABA clearance repair, and dexmedetomidine. The astrocytic GABAergic axis therefore offers a promising candidate target for PND prevention and treatment, and we close by identifying priorities for translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.